Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapy for Constipation

a technology for constipation and bowel disorders, applied in the field of treatment of constipation, can solve the problems of constipation function, inadequacies of bulk-forming laxatives, over-the-counter bulk-forming laxatives,

Inactive Publication Date: 2014-05-01
2294719 ONTARIO
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a method for treating constipation and pain by administering a lipase inhibitor. The lipase inhibitor can be selected from a variety of sources, such as orlistat, atl-962 (cotalstat), gt389-255, and natural lipases like saponins and pancreatic lipase inhibitors. The condition to be treated can include opioid administration, dehydration, lazy bowel, paralytic bowel, menstrual related constipation, bowel resection, and being bedridden. The lipase inhibitor can be administered through various routes such as injection, nasal spray, or orally, and can be formulated as a tablet, pill, or liquid. The patent also describes a composition for treating chronic constipation, which can be in tablet, pill, or liquid form.

Problems solved by technology

For example, opioids may lead to constipation since these agents decrease peristaltic activity in the gastrointestinal (GI) tract.
Because of the mechanisms involved in opioid-induced constipation, some treatments that may be applicable for common, functional constipation are inappropriate for ambulatory-care patients prescribed opioid analgesics.
Also in these patients, the distress of constipation may add to the discomfort already present from pain, and they might decrease or discontinue the opioid to avoid constipation.
Bulk-forming laxatives are typically not appropriate in opioid-induced constipation because peristalsis is inhibited in these patients so stool softener and bowel stimulants are often used.
Some patients may take mild over-the-counter bulk laxatives and fail to mention this to their physician.
This can result in painful, colic-like symptoms.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0033]A 35-year-old female with fibromyalgia presented with chronic pain which is global pain disorder affecting much of her body. She was prescribed opiate medication in the form of MS Contin (60 mg twice a day—BID) for pain management. Since beginning the MS Contin, she suffered from severe constipation. She would often go 7 to 10 days without a bowel movement. She would suffer abdominal discomfort, bloating, and sometimes require manual disempaction due to the severity of her constipation. The patient was given Colace, Sennekot, and bowel stimulants to attempt to correct her chronic constipation related to the pain medication. It was only partially and intermittently successful. She was then given the recommended doses of orlistat (120 mg twice per day orally—BID) with food, and noticed an improvement within 24 hours. Within one week, she had noticed that she had daily bowel movements. She took this new medication for one year and had good well-formed bowel movements most days. S...

example 2

[0034]A 57-year-old female with fibromyalgia being treated with the tricyclic antidepressant amitriptylline suffers from a global pain disorder requiring pain management. She was treated with amitriptyline that is a known therapeutic agent for mild to moderate fibromyalgia. This tricyclic antidepressant is also known for causing dry mouth, blurry vision and constipation. She had tried Colace and Sennekot (senna) with minimal benefit. The patient was given the recommended dosage of cetilistat (60 mg orally once per day with food) for her chronic constipation and within 24 hours, she had had a bowel movement. She continued the cetilistat daily at one pill per day and was able to acquire regular bowel movements daily. She continued the medication for a year and continues to have good success with daily bowel movements. She reported no major side effects. The cetilistat demonstrated the ability to perform as a long-term therapy for constipation, but also for non-opiate medication relate...

example 3

[0035]A 75-year-old man living in a nursing home with mild dementia complained of painful bowel movements causing an anal fissure with bleeding in his rectum. The cause of his constipation was deemed to be due to a combination of non-opiate medications, dehydration, and a lazy bowel. The patient also complained of abdominal distention and some intermittent abdominal discomfort. A number of common prescription laxatives including Colace, senna, and bowel stimulants caused diarrhea. He had abdominal pain with conventional bowel stimulants. He was then given cetilistat (60 mg orally twice daily with food) which resulted in a bowel movement within 24 to 36 hours that was painless and soft. Over the course of two weeks, the anal fissure had healed and the bleeding had stopped. The patient had regular bowel movements daily and his abdominal bloating and abdominal pain had resolved. The cetilistat resolved the constipation in an acute case and allowed for long-term recovery from a constipa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Login to View More

Abstract

A method is disclosed of treating acute, sub-acute or chronic constipation in a patient having a condition requiring such treatment. The method includes administering a lipase inhibitor.

Description

FIELD OF THE INVENTION [0001]The present invention relates to methods and compositions for the treatment of bowel disorders, especially constipation associated with the administration of painkillers.BACKGROUND OF THE INVENTION [0002]Constipation is a frequent side effect of many conditions and medications. For example, opioids may lead to constipation since these agents decrease peristaltic activity in the gastrointestinal (GI) tract. Because of the mechanisms involved in opioid-induced constipation, some treatments that may be applicable for common, functional constipation are inappropriate for ambulatory-care patients prescribed opioid analgesics. Also in these patients, the distress of constipation may add to the discomfort already present from pain, and they might decrease or discontinue the opioid to avoid constipation. Therefore motivating such patients to comply with their opioid therapy also requires an approach for managing constipation[0003]Constipation is broadly defined ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/536A61J1/03A61K31/365
CPCA61K45/06A61J1/035A61K31/365A61K31/536A61P1/10A61K2300/00
Inventor LAMB, BLAIRFAIRLEY, GRANT
Owner 2294719 ONTARIO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com